Clemizole trial for children and adults with Dravet syndrome
Part of Brain & nervous system clinical trials.
This Phase 3 study tests EPX-100 (clemizole) to help reduce seizures in people with Dravet syndrome whose seizures are not fully controlled by current anti-seizure medicines. You may consider this study if your Dravet diagnosis is confirmed and your medical situation fits the specific rules about medicines and seizure causes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your parent/guardian) can sign consent in writing, and your child can assent if needed
- You are at least 2 years old when you join
- You have a confirmed diagnosis of Dravet syndrome with SCN1A genetic mutation
- Your seizures started before 18 months of age and were normal development at the start
- Your brain MRI does not show certain brain shape abnormalities
- Your seizures are not completely controlled by anti-seizure medicines
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called LP352 for children and adults with Dravet syndrome. It compares the study drug to a placebo (a pill with no medicine) to see if it helps reduce seizures.
This early-phase study tests how safe ETX101 is and whether it can help reduce seizures in young children with Dravet syndrome caused by an SCN1A gene change. It mainly enrolls infants and children with a specific type of seizure history and genetic result.
This study follows children with Dravet syndrome caused by a specific SCN1A gene change to understand how the condition develops over time. It may help families know more about what to expect.
This study looks at “GABA signals” in the body/brain to learn more about Dravet syndrome and how it may relate to seizures. If you have Dravet syndrome caused by a specific SCN1A gene change, you may be asked to provide genetic test results and help with study visits so researchers can compare biomarker readings.
This study tests an experimental drug called zorevunersen for people with Dravet syndrome. It aims to see if the drug can reduce seizures and improve safety.
This study uses a special PET-MRI scan to look at a brain chemical pathway linked to serotonin (a mood-regulating substance) in people with Dravet syndrome or certain types of epilepsy, and in healthy volunteers. It may help understand how the brain works in these conditions.
Hear when a new Dravet Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.